open access

Ahead of print
Case report
Published online: 2021-08-31
Get Citation

Initiation of treatment with sacubitril/valsartan during outpatient cardiac rehabilitation program in an octogenarian with heart failure

Piotr Koprowicz1, Jakub Włodarczyk1, Małgorzata Kurpesa2, Jarosław D. Kasprzak2, Tomasz Rechciński2
DOI: 10.5603/FC.a2021.0044
Affiliations
  1. Student Research Society at the Ist Clinic of Cardiology of the Chair of Cardiology of the Medical University of Lodz, Poland
  2. I Klinika i Katedra Kardiologii, Uniwersytet Medyczny w Łodzi

open access

Ahead of print
Case Reports
Published online: 2021-08-31

Abstract

We present the case of including sacubitril/valsartan in an octogenarian patient with congestive heart failure as a part of the outpatient cardiac rehabilitation program. The case shows that apart from hospital use, it is worth considering including this drug during an outpatient cardiac rehabilitation program, because in such conditions the patient is in frequent contact with the treatment center, so his health status may be assessed almost every day.

Abstract

We present the case of including sacubitril/valsartan in an octogenarian patient with congestive heart failure as a part of the outpatient cardiac rehabilitation program. The case shows that apart from hospital use, it is worth considering including this drug during an outpatient cardiac rehabilitation program, because in such conditions the patient is in frequent contact with the treatment center, so his health status may be assessed almost every day.
Get Citation

Keywords

sacubitril, valsartan, ARNI, heart failure, cardiac rehabilitation

About this article
Title

Initiation of treatment with sacubitril/valsartan during outpatient cardiac rehabilitation program in an octogenarian with heart failure

Journal

Folia Cardiologica

Issue

Ahead of print

Article type

Case report

Published online

2021-08-31

DOI

10.5603/FC.a2021.0044

Keywords

sacubitril
valsartan
ARNI
heart failure
cardiac rehabilitation

Authors

Piotr Koprowicz
Jakub Włodarczyk
Małgorzata Kurpesa
Jarosław D. Kasprzak
Tomasz Rechciński

References (7)
  1. Maddox TM, Januzzi JL, Allen LA, et al. Writing Committee. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77(6): 772–810.
  2. Koprowicz P, Włodarczyk J, Kurpesa M, et al. Amiodaron — tarczyca — arytmia. Taniec na linie endokrynologa i kardiologa. Pacjent z poamiodaronowymi zaburzeniami funkcji tarczycy. Folia Cardiol. 2019; 14(3): 294–297.
  3. Tan NY, Sangaralingham LR, Sangaralingham SJ, et al. Comparative effectiveness of sacubitril-valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction. JACC Heart Fail. 2020; 8(1): 43–54.
  4. Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141(5): 352–361.
  5. Romano G, Vitale G, Ajello L, et al. The effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: the "hemodynamic recovery". J Clin Med. 2019; 8(12).
  6. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  7. Lelonek M. Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions. Kardiol Pol. 2020; 78(12): 1199–1205.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl